Status:
COMPLETED
Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia
Lead Sponsor:
Adel Mohamed
Collaborating Sponsors:
Mount Sinai Hospital, Canada
Health Sciences Centre, Winnipeg, Manitoba
Conditions:
Bronchopulmonary Dysplasia (BPD)
Eligibility:
All Genders
Brief Summary
Extreme preterm infants (GA ≤ 28+6 weeks) are at high risk for bronchopulmonary dysplasia (BPD) that has been associated with significant long-term impairment. Lung ultrasound score (LUSs) has the pot...
Detailed Description
Background and Importance: Despite advances in neonatal care and improved survival among immature infants, bronchopulmonary dysplasia (BPD) remained a serious complication among preterm neonates born ...
Eligibility Criteria
Inclusion
- GA ≤ 28+6 weeks Admitted to the NICU at Mount Sinai Hospital or Health sciences Centre-Winnipeg consent obtained.
Exclusion
- Infants who are born at \> 28 weeks GA, or have congenital or chromosomal abnormalities, or parents declined consent will be excluded.
- \-
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 25 2021
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT04756297
Start Date
July 1 2019
End Date
February 25 2021
Last Update
April 1 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3C3H8
2
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G1X5